Pembrolizumab-The U.S. Food and Drug Administration (FDA) has approved the combination of Welireg (belzutifan) and Pembrolizumab (Keytruda) for the treatment of certain patients with renal cell carcinoma (RCC), the most..
Hepatitis -Glaucoma is a leading cause of irreversible blindness worldwide, primarily caused by damage to the optic nerve. Elevated intraocular pressure (IOP) is one of the most significant risk factors for glaucoma progression….
Physician -Atopic dermatitis is a chronic, relapsing inflammatory skin disease, often emerging in early childhood, with symptoms of itching, redness, scaling, and skin barrier dysfunction.In young children, the disease can affect large body surface areas and significantly impact quality of life — disrupting sleep,
FDA – U.S. Food and Drug Administration (FDA) approved Belzutifan (brand name Welireg, developed by Merck & Co.) for the treatment of locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL)
FDA Approves Ekterly – Generic name: sebetralstat is a first-in-class oral, on-demand medication developed for the treatment of acute attacks in patients with hereditary angioedema (HAE) aged 12 years and older. It marks a significant advancement in HAE management, offering the first non-injectable option for immediate treatment of these potentially life-threatening swelling episodes.
The U.S. Food and Drug Administration (FDA) has officially approved Tremfya (guselkumab) for the treatment of adults suffering from…
Stroke is one of the leading causes of disability and death worldwide, with ischemic stroke accounting
In a significant move affecting the weight-loss and diabetes treatment landscape, the U.S. Food and Drug Administration (FDA) has..
